parsaclisib + bendamustine + rituximab

Parsaclisib + bendamustine + rituximab is an investigational combination regimen for hematologic malignancies, notably indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. **Parsaclisib** is a selective PI3Kδ inhibitor (small molecule) that blocks PI3Kδ-mediated B-cell survival and proliferation signaling, and has shown synergistic activity in combination regimens. **Bendamustine** is an alkylating agent (small molecule) causing DNA crosslinking and apoptosis in dividing cells. **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, leading to cell lysis via immunologic mechanisms. This triple regimen is not a marketed product but is explored in clinical trials to improve efficacy for lymphoma patients, particularly those not responding to standard therapies.